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cost-effectiveness ratio (ICER) for the comparison of imiquimod versus no treatment 
was 1,227 PLN per gained complete clearance assessed clinically and histologically, 
and 1,138 PLN per gained complete clearence assessed only histologically. CONCLU-
SIONS: Imiquimod is more effective and more expensive than no treatment in patients 
with superﬁcial basal cell carcinoma and contraindication to surgical intervention and 
cryotherapy. ICER value is below the acceptable threshold, therefore imiquimod 
therapy is considered as cost-effective treatment in Poland.
PCN100
COST-EFFECTIVENESS OF ANASTROZOLE AS ADJUVANT TREATMENT 
FOR EARLY STAGES BREAST CANCER IN POSTMENOPAUSAL WOMEN
Rudakova AV
Military Medical Academy, St-Petersburg, Russia
OBJECTIVES: To evaluate the cost-effectiveness of anastrozole (1 mg/day) versus 
tamoxifen (20 mg/day) as adjuvant treatment for early stages breast cancer in post-
menopausal women. METHODS: Cost-effectiveness analysis was performed. Markov 
model was built based on the results of ATAC and ARNO 95 studies. Two strategies 
of adjuvant therapy—initial therapy with anastrozole and switching to anastrozole 
after two years treatment with tamoxifen were evaluate in the model, total duration 
of adjuvant therapy followed in the model was 5 years. The time horizon was equal 
to patient’s life expectancy. RESULTS: The results demonstrated that initial adjuvant 
therapy with anastrozole is cost-effectiveness in patients with high risk of relapse and 
also in the group of patients younger then 55 years. The cost-effectiveness ratio in the 
basis variant (population included into ATAC-study, age at the start of adjuvant 
therapy—65 years) was 1161.4 thousand Rub/QALY (a25,800/QALY). In early debut 
of cancer at the age of  55 years, the cost-effectiveness ratio was 728.8 thousand 
Rub/QALY (a16,200/QALY). From the economic point of view the effective therapy 
scheme is switching patients to anastrozole after two years of tamoxifen treatment. 
The cost-effectiveness ratio of this scheme is estimated from 624,6 thousand Rub/
QALY (a13,900/QALY) in patients at the age of 55 years to 1209.7 thousand Rub/
QALY (a26,900/QALY) in patients at the age of 70 years. In the basis variant (popula-
tion included into ARNO 95-study age at the start of adjuvant therapy—60 years) 
the ratio was 776.4 thousand Rub/QALY (a17,300/QALY). CONCLUSIONS: The 
switching the patients in postmenopause to anastrozole after two years of tamoxifen 
treatment may be considered reasonable from the economic point of view in Russia. 
The initial adjuvant treatment with anastrozole in patients with high risk of relapse, 
not belonging to elder age groups, is also economically reasonable.
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OBJECTIVES: A decision-analysis model parameterised for Scotland was used to 
evaluate the cost-effectiveness of intranasal fentanyl spray (INFS, Instanyl®) compared 
with oral transmucosal fentanyl citrate lozenge (OTFC, Actiq®) and oral transmucosal 
fentanyl buccal tablet (FBT, Effentora®) for the treatment of BTCP. METHODS: The 
model estimated costs and beneﬁts associated with INFS, OTFC and FBT. Relative           
analgesic efﬁcacy of the interventions was derived from a meta-analysis of six ran-
domised controlled trials. The percentage of BTCP avoided was estimated from the 
pain intensity (PI) course of a BTCP episode with and without treatment. Resource 
use and quality of life gains were estimated based on reductions in PI. The relationship 
between PI and utility was derived from a time-trade off study in the UK general 
population. Resource use and unit cost data were obtained from the literature and 
validated by clinical experts. Uncertainty in the source data was incorporated by        
means of one-way sensitivity analyses, probabilistic sensitivity analyses and different 
scenario analyses. RESULTS: For the base-case scenario, 3 BTCP episodes/day, a 
background PI of 2, a time-horizon of 365 days and equal prices for INFS and OTFC 
irrespective of dosage were assumed. With INFS, 55% of BTCP (95% Uncertainty 
Interval: 45–66%) was avoided, greater than expected with OTFC (29%; 21–39%) 
or FBT (31%; 25–39%). INFS was dominant versus OTFC and cost-effective versus 
FBT. Despite the uncertainty in the source data, there is a          99% probability that INFS 
is the most cost-effective intervention. Sensitivity and scenario analyses did not change 
the main conclusion. CONCLUSIONS: Greater efﬁcacy of INFS in pain reduction is 
expected to reduce medical resource use and result in cost-savings for health care 
providers and quality of life gains for patients. INFS is a cost-effective treatment for 
BTCP compared with OTFC and FBT in Scotland.
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OBJECTIVES: Based on results from the HERceptin Adjuvant Trial (HERA) with a 
median follow-up time of 1 year, trastuzumab is licensed and reimbursed for the 
treatment of HER2 early breast cancer (EBC) in Italy since 2006. As the risk of 
recurrence reduces overtime, hazard ratios in breast cancer trials usually increase as 
more follow-up data is available. Longer term follow-up data were recently reported 
for 2 and 4 years, the latter though being heavily confounded by extensive cross-over 
of the HERA comparator arm and hence unusable. The objective of this analysis was 
therefore to determine the cost effectiveness of 1-year treatment with trastuzumab vs 
observation, based on results from the 2-year follow up data. METHODS: A pub-
lished Markov model based on the initial HERA results was revised and updated to 
incorporate the hazard ratios from the 2-year follow up data to reﬂect trastuzumab’s 
impact on disease progression. The treatment effect reported was applied for the ﬁrst 
4 years of the model. An Italian health care payer perspective was adopted. Medication 
and acquisition costs were taken from published sources whereas health state and 
event costs were derived from costing study conducted in Tuscany. A lifetime horizon 
was chosen. Incremental cost-effectiveness ratios were expressed as cost per quality 
adjusted life year (QALY). Costs and QALYs were discounted at 3.0% p.a. Sensitivity 
analyses were performed. RESULTS: The analysis showed that after completion of 
adjuvant chemotherapy, treatment with trastuzumab resulted into additional 1.81 life 
years and 1.62 QALYS gained per patient compared to observation only, at an incre-
mental mean total cost of a18,022. The ICER was estimated at a11,131/QALY, which 
is well in line with previously published analyses. CONCLUSIONS: Using more recent 
data from the HERA trial, Trastuzumab was determined to remain a cost effective 
treatment option for HER2ve EBC in the Italian setting.
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OBJECTIVES: Following broadening of the EMEA license for ﬁrst-line treatment 
of previously untreated patients with chronic lymphocytic leukaemia (CLL) with     
rituximab added to chemotherapy, we evaluated the cost-effectiveness of rituximab 
in combination with commonly used chemotherapy regimen of ﬂudarabine plus 
cyclophosphamide (R-FC) versus ﬂudarabine plus cyclophosphamide (FC) from the 
perspective of the Spanish national health care system. METHODS: A three stage 
Markov model including progression-free survival (PFS), progression state and mortal-
ity was developed using published results from the randomized clinical trial CLL-8 
evaluating PFS in patients with CLL. Rates of disease progression were derived       
from a Weibull model, mortality rates were obtained from Kaplan-Meier and Spanish 
age-speciﬁc mortality tables. Patient elicited utilities were applied to PFS and pro-
gressed health states. The cost of drugs, supportive care, and quality-adjusted life 
years (QALY) were estimated over a period of 10 years, the median survival for CLL, 
and discounted at 3.5 per annum. Univariate and probabilistic (Monte Carlo simula-
tion) sensitivity analysis were performed. RESULTS: The addition of rituximab to 
chemotherapy increased life-years gained (LYG) and QALYs by 0.669 and 0.617 
years per patient, respectively, compared to chemotherapy alone. The incremental 
cost per LYG and QALY gained was a17,726 and a19,220, respectively. Cost-effective 
results were obtained with Monte Carlo simulation. Univariate sensitivity analyses 
indicated the results were robust, and most sensitive to time horizon, with a threshold 
value at year 7, from which the R-FC regimen is cost-effective. CONCLUSIONS: 
The model demonstrated that the addition of rituximab to ﬂudarabine plus cyclophos-
phamide (FC) regimen increased life and quality-adjusted life expectancy and is a 
cost-effective ﬁrst-line treatment option for patients with chronic lymphocytic 
leukaemia.
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OBJECTIVES: The objective of the study was to evaluate the cost-effectiveness of 
erlotinib compared to docetaxel for the treatment of advanced non small cell lung 
cancer (NSCLC) in China. METHODS: A Markov health-state model was designed 
to estimate the direct medical costs and outcomes (life years and QALYs gained) of 
treating advanced NSCLC. The model included three health states—progression free 
survival (PFS), post progression free survival (PPF) and death. The evolution of a 
cohort of patients was simulated along 2 years with monthly cycles. Survival and time 
to progression were retrieved from 2 pivotal clinical trials. From the perspective of 
China’s health insurance system, resource use was calculated based on a questionnaire 
survey from clinical expert panels. A discounting rate at 3% was used to discount 
medical costs happening at different years. A univariate sensitivity analysis was per-
formed to understand the key drivers and general sensitivity of the model. RESULTS: 
The model results showed that the utilization of erlotinib treatment in NSCLC can 
prolong 0.047 QALYs (0.038 life years), compared to the docetaxel treatment. The 
total cost per patient was lower with erlotinib (US$23,351) than with docetaxel 
(US$24,846). The lower cost and better efﬁcacy associated with erlotinib makes it a 
dominant treatment strategy in comparison to docetaxel. CONCLUSIONS: According 
to this model, erlotinib is more cost-effective than docetaxel in treating advanced 
NSCLC, with savings for the China’s health insurance system.
